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Summary 
The mechanisms underlying the selective degeneration of medium spiny neurons 
(MSNs) in Huntington’s disease (HD) remain largely unknown. CTIP2, a transcription 
factor expressed by all MSNs, is implicated in HD pathogenesis due to its 
interactions with mutant huntingtin. Here we report a key role for CTIP2 in protein 
phosphorylation via governing protein kinase A (PKA) signaling in human striatal 
neurons. Transcriptomic analysis of CTIP2-deficient MSNs implicates CTIP2 target 
genes at the heart of cAMP-Ca2+ signal integration in the PKA pathway. These 
findings are further supported by experimental evidence of a substantial reduction in 
phosphorylation of DARPP32 and GLUR1, two PKA targets in CTIP2-deficient 
MSNs. Moreover, we show that CTIP2-dependent dysregulation of protein 
phosphorylation is shared by HD hPSC-derived MSNs and striatal tissues of two HD 
mouse models. Our study therefore establishes an essential role for CTIP2 in human 
MSN homeostasis and provides mechanistic and potential therapeutic insight into 
striatal neurodegeneration. 
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Introduction 
Inhibitory -amino butyric acid (GABA)-releasing medium spiny neurons (MSNs) are 
the principal projection neurons of the basal ganglia, receiving inputs from both 
glutamatergic cortical neurons and midbrain dopaminergic neurons. DARPP32 is a 
class-defining protein marker for striatal MSNs and a central mediator of 
dopaminergic and other first messenger signaling in these cells. Specifically, 
phosphorylation of DARPP32 at threonine 34 (pDARPP32-Thr34) by protein kinase 
A (PKA), following dopamine D1 receptor activation, is critically involved in regulating 
electrophysiological, transcriptional and behavioral responses of MSNs to 
physiological and pharmacological stimuli, including antidepressants, neuroleptics, 
and drugs of abuse (Yger and Girault, 2011). Thus, these findings point to an 
important role for PKA-regulated phosphorylation of DARPP32 in MSN health, with 
major implications for neurological disorders. 
CTIP2 (also known as BCL11B) is a transcription factor expressed by all MSNs and 
is required for MSN development and transcriptional regulation of striatal genes 
(Arlotta et al., 2008; Onorati et al., 2014). CTIP2 deficiency results in structural 
striatal defects, impaired spatial learning and working memory deficits in mice 
(Arlotta et al., 2008; Simon et al., 2016). Furthermore, CTIP2 protein level is reduced 
in both human and rodent mutant huntingtin (mHTT)-expressing cells prior to the 
onset of MSN degeneration (Langfelder et al., 2016; Ring et al., 2015), pointing to a 
role for CTIP2 in Huntington’s disease (HD) pathogenesis. These findings have led 
us to hypothesize that CTIP2 may play an important role in conferring regional 
specificity of HD neurodegeneration that cannot be explained by the ubiquitous 
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expression of the mHTT. However, whether CTIP2 deficiency directly leads to 
increased MSN vulnerability and dysfunction remains to be demonstrated. 
Using CRISPR/Cas9 genome-edited human embryonic stem cells (hESCs) as a 
model, we uncover a role for CTIP2 in regulating protein kinase and phosphatase 
levels and activity and subsequently phosphorylation of DARPP32-Thr34 in MSNs. 
We show for the first time that deficits in PKA-dependent protein phosphorylation 
occur in human and mouse HD MSNs, potentially due to CTIP2- and mHTT-co-
regulated molecular signaling abnormalities as suggested by transcriptomic analysis. 
Our study provides novel evidence of a central role for CTIP2 in human MSN 
homeostasis and supports the hypothesis that CTIP2 may mediate regional 
specificity of HD pathogenesis. 
Results 
CTIP2-deficiency does not compromise the generation of medium spiny 
neurons from hESCs 
Homozygous CTIP2 knock-out hESC lines were generated using the CRISPR/Cas9-
assisted genome editing technology with guide RNAs (gRNAs) targeting exon 2 of 
the CTIP2 gene (Figure S1A-S1D). To investigate whether CTIP2 deficiency affects 
the generation of MSNs from hESCs, we performed striatal neural differentiation on 
CTIP2KO and control lines using an established protocol (Arber et al., 2015). At 20 
days in vitro (DIV), both control and CTIP2KO hESCs gave rise to high yields of cells 
expressing lateral ganglionic eminence (LGE) markers GSX2, FOXP2, ISL1 and 
MEIS2, subpallial marker ASCL1, with very few TBR1+ cortical cells (Figures 1A, 1B 
and S2). These LGE-like progenitors differentiated into 35–40% DARPP32+, FOXP1+ 
and FOXP2+ MSNs by 40 DIV and maintained MSN identity for the subsequent 20-
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day period (Figure 1C-1F). Taken together, these results indicate that the loss of 
CTIP2 does not affect the yield of nascent and mature MSNs derived from hESCs. 
CTIP2-deficient MSNs display increased vulnerability to oxidative stress 
We then asked whether loss of CTIP2 would compromise MSN health. To this extent 
we investigated oxidative stress-dependent cell death using the nitric oxide donor S-
nitroso-N- acetylpenicillamine (SNAP), which was previously shown to generate 
reactive oxygen species and induce oxidative stress (Wei et al., 2000). After a 24-
hour exposure of cells to SNAP we observed a 2-fold greater increase in apoptosis 
in CTIP2KO MSNs compared to control neurons (Figure 1G). This phenotype was 
rescued by a 2-hour pre-treatment with the neuroprotective and anti-apoptotic agent 
amentoflavone (Figure 1G ‘MSN’), a drug previously shown to reduce neuronal 
damage via decreasing nitric oxide production in response to apoptotic stimuli 
(Zhang et al., 2015). We next checked if CTIP2-dependent cell death deficits were 
MSN-specific by analyzing differentiated CTIP2-expressing cortical neurons and 
dopamine neurons that do not express CTIP2. Interestingly, cortical neurons were 
less vulnerable to oxidative stress than MSNs, with CTIP2KO neurons showing only 
a trend towards a more severe phenotype than control (Figure 1G ‘CTX’). Oxidative 
stress-dependent cell death levels were not affected by CTIP2KO in dopaminergic 
neurons (Figure 1G ‘DA’). This data suggests that CTIP2 plays a neuroprotective 
role against oxidative stress that is restricted to MSNs. 
Genome-wide transcriptome analysis highlights a role for CTIP2 in PKA-
regulated protein phosphorylation 
To investigate the molecular mechanisms and pathways leading to pathological 
changes in CTIP2-deficient MSNs, we performed whole-transcriptome RNA 
sequencing (RNA-seq) analysis of CTIP2KO #4 and control MSN cultures at 20 and 
6 
40 DIV (MSN20 and MSN40, respectively). Global principal component analysis 
showed clear sample segregation based on genotype and developmental stage 
(Figure S3A). Analysis of protein-coding genes identified 4903 and 5835 
differentially expressed genes (DEGs) for MSN20 and MSN40, respectively (Figure 
S3B and Table S1). Moreover, MSN20 and MSN40 DEGs were enriched for human 
striatum-specific genes and significantly associated with the Ctip2 loss-of-function 
study in mouse striatum (Arlotta et al., 2008; Onorati et al., 2014) (Table S2). 
Amongst these striatal genes are EBF1, LMO3, CNR1, DRD1, DRD2, SST, REC8, 
GRM1 and PDE5A, which were all downregulated in CTIP2KO cells. 
We identified mitochondrial dysfunction, oxidative phosphorylation, calcium signaling 
and HD signaling among the significantly dysregulated pathways at both time points 
(Figures 2A, 2B, S3C and Table S2). Intriguingly, genes concerning dopamine-
DARPP32 feedback in cAMP signaling, PKA and CDK5 signaling were found to be 
significantly altered in mature MSNs (Figure 2B). Also, significant dysregulation of 
synaptic signaling was detected for major neurotransmitters involved in MSN 
function, including dopamine, glutamate, and GABA (Figures 2B and S3C). 
Dopamine and glutamate coupled with a cross-talk between PKA and CDK5 kinases 
are major regulators of DARPP32 phosphorylation in MSNs. Interestingly, known 
CTIP2 target genes concerning protein phosphorylation, serine/threonine kinase 
activity, Ca2+ transport and cation channel activity were significantly dysregulated in 
our CTIP2KO datasets (Table S3) (Tang et al., 2011). Moreover, four CTIP2 target 
genes (ADD3, CNGA3, DUSP16, PRKCE) appeared in the PKA gene set (Figure 
2C), two of which along with several PKA signaling genes were validated in 
independent samples from all three CTIP2KO lines (Figure S3D). Dysregulation of 
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ADD3 and CNGA3 predicted to inhibit activation of cAMP dependent PKA (Figure 
3A and Table S2). 
CTIP2 regulation of PKA-dependent DARPP32-Thr34 and GLUR1-Ser845 
phosphorylation in MSNs 
PKA is responsible for phosphorylation of DARPP32-Thr34 and GLUR1-Ser845 
(Bibb et al., 1999). The predicted reduction in PKA activity from the RNA-seq 
analysis prompted us to investigate the phosphorylation status of DARPP32 and 
GLUR1. We observed an almost 50% decrease in both pDARPP32-Thr34 and 
pGLUR1-Ser845 levels with no change in total DARPP32 or GLUR1 protein levels in 
CTIP2-deficient neurons at 40 DIV (Figure 3B and 3C). When phosphorylated at 
Thr34, DARPP32 acts as an inhibitor of protein phosphatase 1 (PP1) by directly 
binding to its catalytic subunit α (PPP1CA) (Hemmings et al., 1984). Therefore, we 
asked whether reduced presence of pDARPP32-Thr34 in CTIP2KO MSNs had an 
impact on PP1 protein levels and discovered that PPP1CA content was significantly 
increased in CTIP2KO samples (Figure 3D and 3E). 
To gain insight into potential mechanisms that led to the reduction of pDARPP32-
Thr34, we explored major regulators of DARPP32 phosphorylation in MSN cultures. 
Protein phosphatase 3 (PP3, formerly PP2B), is known to dephosphorylate 
DARPP32-Thr34 in a Ca2+-dependent manner (Nishi et al., 1999). Western blot 
analysis revealed a significant increase in α (PPP3CA) and γ (PPP3CC) but not β 
(PPP3CB) isozymes of PP3 catalytic subunits in CTIP2-deficient MSNs (Figure 3D 
and 3E). Moreover, we observed significantly reduced levels of PKA catalytic 
subunits and elevated levels of CDK5R1, a neuron specific activator of CDK5, in 
CTIP2KO cultures compared to controls (Figure 3F and 3G), although the level of 
CDK5 itself was not affected by CTIP2 deficiency. Our data demonstrate that the 
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levels of MAP2, a pan neuronal protein, were similar in CTIP2KO and control 
cultures (Figure 3H), providing further support that the observed changes in protein 
kinase and phosphatase levels attribute to CTIP2 deficiency. 
Finally, we demonstrate that reduction in pDARPP32-Thr34 levels is directly caused 
by the loss of CTIP2 in MSNs. To this extent we re-introduced CTIP2 into CTIP2KO 
#4 MSNs via viral delivery of CTIP2 transgene in post-mitotic MSN neurons and 
determined levels of DARPP32 phosphorylation (Figures 3I and S1E). Acute 
restoration of CTIP2 expression in MSNs completely rescued DARPP32-Thr34 
phosphorylation deficits without affecting total DARPP32 levels. Taken together 
these findings provide strong evidence for a role for CTIP2 in regulating PKA-
dependent protein phosphorylation in MSNs. 
CTIP2-mediated signaling abnormalities and aberrant PKA-dependent protein 
phosphorylation are shared by human and rodent HD MSNs 
Since CTIP2 level is reduced in several HD models that share some of the deficits 
with CTIP2KO MSNs, we investigated potential overlap between CTIP2- and mHTT-
mediated transcriptomic changes by comparing our MSN20 and MSN40 DEGs with 
four publicly available datasets of human and mouse HD models (Hodges et al., 
2006; Langfelder et al., 2016; Lim et al., 2017; Ring et al., 2015). This analysis 
indeed revealed genes co-regulated by CTIP2 and mHTT at both time points (Table 
S4). We compiled a list of 1906 and 1976 genes from our MSN20 and MSN40 
DEGs, respectively, that were concordantly dysregulated (FDR<0.01) in at least one 
HD gene expression dataset (Table S4). Further analysis highlighted HD signaling, 
oxidative phosphorylation, mitochondrial dysfunction, DNA repair (MSN20) and PKA, 
ERK/MAPK and dopamine-DARPP32 feedback in cAMP signaling (MSN40) among 
the top 20 biological pathways affected by the co-regulated genes (Table S4). These 
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results suggest that the signaling abnormalities caused by CTIP2 deficiency are also 
present in mHTT-expressing MSNs. 
To strengthen this observation and provide the first experimental support, we 
examined DARPP32 and Glur1 phosphorylation, and Ppp3ca and Ppp3cc 
phosphatase levels in animal and human cell models of HD. More than a 50% 
decrease in pDarpp32-Thr34 levels was observed in striatal homogenates of R6/1 
and Q175 mice compared to wild-type (WT) littermates (Figure 4A and 4B). 
Similarly, pGluR1-Ser845 levels were greatly reduced in both HD mouse models 
(Figure 4A and 4B). This decrease in phosphorylation was independent of the 
changes in total protein levels. In line with findings in human CTIP2KO neurons, 
Q175 mouse striata contained significantly higher levels of Ppp3cc than WT 
littermates (Figure 4C and 4D). However, no significant change was observed in the 
levels of Ppp3ca between WT and the two HD mouse models (Figure 4C and 4D). 
Moreover, an 80% decrease in pDARPP32-Thr34 levels was found in MSN cultures 
at 40 DIV derived from three independent HD human pluripotent stem cell (hPSC) 
lines compared to control cells (Figure 4E and 4F). Taken together, these results 
suggest that CTIP2 hypofunction in striatal MSNs may contribute to neuronal cell 
pathologies observed in HD. 
Discussion 
We have developed an efficient and versatile platform for investigating the role of 
transcription factor CTIP2 in human MSN development and homeostasis. CTIP2-
driven DEGs identified in the current study are significantly enriched in striatal genes 
associated with both direct and indirect pathways in the basal ganglia, which is in 
line with previous findings in mice (Arlotta et al., 2008). These Ctip2-deficient mice 
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exhibited normal expression of immature MSN markers (Meis2 and Nolz1) in the 
developing LGE at embryonic day 14.5. However, the number of Darpp32+ neurons 
was significantly reduced in the newborn striatum. It remained unclear therefore 
whether Darpp32+ MSNs could initially be generated in Ctip2-/- mice. Using a panel 
of LGE and postmitotic MSN markers, our study provides the first evidence that 
CTIP2 deficiency does not compromise the initial birth of MSNs from hESCs. 
Moreover, this work demonstrates that CTIP2 plays a neuroprotective role against 
oxidative stress and is essential for maintaining striatal MSN characteristics. Notably, 
we uncover that CTIP2 deficiency causes an imbalance between protein 
kinase/phosphatase levels and activity, and subsequently reduced PKA target 
phosphorylation in MSNs, a novel cellular pathology shared by human and mouse 
MSNs carrying mHTT. Furthermore, our transcriptomic analysis highlights 
involvement of CTIP2 target genes in regulating Ca2+ signaling and kinase activity. 
ADD3 and CNGA3 regulate synaptic plasticity, Ca2+ transport and activation of 
cAMP-dependent PKA and were significantly downregulated in CTIP2-deficient 
MSNs (Bosia et al., 2016; Macneil et al., 1985). This provides mechanistic insight 
into how CTIP2 hypofunction may contribute to the reduced PKA-dependent protein 
phosphorylation via dysregulating Ca2+-mediated cAMP activity in CTIP2-deficient 
MSNs, and potentially in HD (Figure 4G). 
PKA and CDK5 phosphorylate DARPP32 and glutamate receptors, to modulate 
excitability of striatal synapses and postsynaptic signaling in MSNs, in response to 
dopamine and glutamate stimulation (Bibb et al., 1999). Lower PKA activity has been 
associated with proteasome impairments in two HD mouse models and mHTT-
expressing striatal cells (Lin et al., 2013). We demonstrate reduced phosphorylation 
levels of PKA targets DARPP32-Thr34 and GLUR1-Ser845 in both CTIP2KO and 
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mHTT-expressing MSNs, potentially due to inhibited activation of PKA. Furthermore, 
we provide evidence that DARPP32 phosphorylation deficits can be directly rescued 
by restoring CTIP2 levels in KO MSNs. 
When phosphorylated, pDARPP32-Thr34 acts as an inhibitor of PP1, which normally 
dephosphorylates PKA targets (Greengard et al., 1999). Intriguingly, PP1 also 
regulates phosphorylation of HTT at Thr3 site and increases its aggregation 
properties (Branco-Santos et al., 2017). Thus, CTIP2 hypofunction-mediated 
disinhibition of PP1 activity due to reduced pDARPP32-Thr34 availability would 
induce mHTT aggregation in HD MSNs. A higher affinity for interaction between 
Ctip2 and mHtt than normal Htt was demonstrated in three independent HD mouse 
models, and mHtt was shown to impair transcriptional function of Ctip2 (Desplats et 
al., 2008). Thus, abnormal kinase/phosphatase activity in CTIP2-deficient and HD 
MSNs, where mHTT interacts and disrupts CTIP2 function, may underlie not only 
disruption of synaptic signaling in the striatum but also mHTT aggregate formation 
eventually leading to MSN degeneration and cell death. 
The impact of our study may go beyond the HD field as genetic mutations associated 
with schizophrenia were found in genes enriched in MSNs (Skene et al., 2018). 
Reduced levels of full-length DARPP32 and increased levels of DARPP32 isoforms 
lacking the crucial residue Thr34 were reported in schizophrenia patients (Kunii et 
al., 2014), which would have major implications for MSN regulation by dopamine. 
Moreover, mutations in the CTIP2 gene, causing either CTIP2 haploinsufficiency or a 
truncated CTIP2 protein, have been linked to a neurodevelopmental delay with 
speech impairment and intellectual disability in patients (Lessel et al., 2018). 
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In conclusion, we have explored CTIP2-regulated molecular mechanisms in striatal 
neurons and demonstrated an essential role for CTIP2 in human MSN homeostasis. 
Our study provides a robust in vitro framework to study neurodevelopmental 
phenotypes and MSN dysfunction in the context of neurological disorders, with 
modulation of PKA-dependent protein phosphorylation representing a potential new 
therapeutic target. 
Experimental Procedures 
CRISPR Design and Targeted Mutagenesis 
Guide RNAs were synthesized as RNAs by in vitro transcription and transfected into 
HUES9 iCas9 hESCs as described by Gonzalez et al (Gonzalez et al., 2014). 
Cell Culture and MSN Differentiation 
MSNs were differentiated from the following hPSC lines: HUES9 iCas9 and genome-
edited derivatives (#4, #33, #34), HD hESCs (46Q and 51Q), and HD hiPSCs (71Q; 
see Supplemental Experimental Procedures for HD line details). MSNs were 
obtained and maintained as described previously (Arber et al., 2015). 
Immunocytochemistry 
Cells were incubated with primary antibodies overnight at 4oC followed by Alexa-
Fluor secondary antibodies for 1 hour. Staining quantification was acquired manually 
in ImageJ (imagej.net) from >5,000 cells/sample blind to the experimental condition. 
RNA Sequencing 
Paired-end sequencing was performed at Oxford Genomic Centre on an Illumina 
HiSeq 4000 (Illumina, San Diego, USA). RNA-seq data reported in this paper are 
available with the SRA accession number SRP150394. 
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Study Approval 
Animal work was done under UK Home Office personal and project licenses in 
accordance with the requirements of the UK Animals (Scientific Procedures) Act 
1986. Animals were group-housed and received water and food ad libitum. 
Western Blot 
Equal amounts of proteins for each sample were separated on 4-12% Bolt Bis-Tris 
Plus gels (Thermo Fisher Scientific) and transferred via electro-blotting to a PVDF 
membrane (0.45 µm pore size, GE Healthcare). Membranes were incubated with 
primary antibodies overnight at 4°C followed by secondary antibodies for 1 hour. All 
blot images were quantified in ImageJ blind to the experimental condition. 
Statistical Analysis 
Statistical analysis was performed using one- or two-way ANOVA tests and 
considered statistically significant at p<0.05. Sample sizes for each test are indicated 
in the figure legends as n=n1,n2,n3, where n1 and n2 are the number of control and 
CTIP2KO (or HD) samples, respectively, from n3 independent experiments. 
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Figure Legends 
Figure 1 - CTIP2KO MSNs acquire normal striatal cell identity but present with 
increased vulnerability to oxidative stress. 
(A,B) LGE-like progenitors in control and CTIP2KO cultures at 20 DIV labelled and 
quantified for GSH2, FOXP2, ISL1 and MEIS2 [n=3,9,3]. 
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(C,D) MSNs in control and CTIP2KO cultures at 40 and 60 DIV labelled and 
quantified for DARPP32 [n=3,9,3]. 
(E,F) MSNs in control and CTIP2KO cultures at 40 and 60 DIV labelled and 
quantified for FOXP1 and FOXP2 [n=3,7,≥2]. 
(G) Pre-treatment of MSNs with 50 μM amentoflavone (AF) for 2 hours protects them
from SNAP-induced cell death at 40 DIV. Similar vulnerability to oxidative stress is 
observed between control and CTIP2-deficient groups in both cortical neurons (CTX) 
and dopaminergic (DA) neurons [n=3,9,3]. 
(A,C,E) Scale bars: 50μm. (B,D,F) One-way ANOVA; n.s., not significant. (G) Two-
way ANOVA; MSN: *,***p<0.05, 0.001; &&&p<0.001. Data are presented as mean ± 
SEM for each genotype, with the means for individual clones indicated by red-
shaded circles beside CTIP2KO data. 
See also Figures S1-2. 
Figure 2 - RNA-seq analysis highlights a role for CTIP2 in PKA-regulated 
protein phosphorylation in hESC-derived MSNs. 
Pathway Analysis (IPA) of MSN20 (A) and MSN40 (B) CTIP2KO DEGs shows 
significant enrichment of genes regulating mitochondrial function at 20DIV, PKA and 
CDK5 signaling as well as dopamine-DARPP32 feedback in cAMP signaling at 
40DIV (full gene set lists for both timepoints are presented in Table S2). 
(C) Differential expression statistics for MSN40 DEGs within the PKA gene set at fold
change threshold of |1.4|, with direct CTIP2 targets highlighted in green. Genes 
analyzed by RT-PCR in independent control and CTIP2KO MSN samples are 
indicated in italic, with red asterisks marking validated differential expression. 
See also Figure S3 and Tables S2-3. 
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Figure 3 - PKA-dependent DARPP32-Thr34 and GLUR1-Ser845 
phosphorylation is regulated by CTIP2 in MSNs. 
(A) Within the PKA signaling gene set, CTIP2 target genes (ADD3, CNGA3) were
significantly dysregulated and their change predicted to inhibit activation of cAMP 
dependent PKA. 
(B,C) Phosphorylation of PKA targets DARPP32-Thr34 and GLUR1-Ser845 is 
greatly reduced in CTIP2KO versus control MSNs [(C) left: n=8,17,4; right: 
n=10,21,4]. 
(D,E) Part of PKA signaling pathway, levels of protein phosphatase 1 (PP1) and 3 
(PP3) catalytic subunits are significantly increased in CTIP2KO versus control MSNs 
[(E) from left, top row: n=9,20,4; n=8,16,3; bottom row: n=5,12,3; n=5,10,3]. 
(F,G) Compared to control cells, CTIP2KO MSNs contain reduced levels of PKA 
catalytic subunits (PKAcat) and increased levels of CDK5R1, a neuron specific 
activator of CDK5 [(G) from left: n=9,22,4; n=8,16,3]. 
(H) Quantification of MAP2 levels shows no differences between control and
CTIP2KO MSN cultures [n=10,22,4]. 
(I) Reduced phosphorylation of DARPP32-Thr34 in CTIP2KO #4 MSNs is rescued
by restoring CTIP2 levels [n=6,6,3]. 
(C, E, G, H, I) One-way ANOVA; *,**,***,****p<0.05, 0.01, 0.001, 0.0001; n.s., not 
significant. Data are presented as mean ± SEM for each genotype, with the means 
for individual clones indicated by red-shaded circles beside CTIP2KO data. 
See also Figures S1E and S4. 
Figure 4 - PKA-dependent protein phosphorylation deficits are shared by 
human and rodent mHTT-expressing MSNs. 
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Images (A) and quantification (B) showing a great mHtt-dependent decrease in 
pDarpp32-Thr34 and pGluR1-Ser845 levels in R6/1 and Q175 HD mouse models 
[(B) n=3,3]. 
Images (C) and quantification (D) of two catalytic subunits of Pp3, Ppp3ca and 
Ppp3cc, showing a mHtt-dependent increase in Ppp3cc levels in R6/1 and Q175 
mice [(D) n=3,3]. 
Images (E) and quantification (F) showing a great mHtt-dependent decrease in 
pDARPP32-Thr34 levels in MSNs derived from three independent HD hPSC lines 
[(F) n=2,6,2]. 
(B, D, F) One-way ANOVA; **,***,****p<0.01, 0.001, 0.0001; n.s., not significant. 
Data are presented as mean ± SEM. 
(G) Some of the CTIP2-regulated intracellular events are depicted in a healthy (left)
versus CTIP2KO and HD (right) MSN. CTIP2 target genes in the PKA gene set are 
shown in red and some of their interactions with members of the PKA signaling 
pathway are indicated with an asterisk. Decreased PKA signaling in CTIP2KO 
neurons is likely mediated through lower levels of catalytic subunits of PKA available 
and a loss of pDARPP32-Thr34-regulated inhibition of phosphatase PP1. Most of 
these molecular changes are also present in mHTT-expressing cells, suggesting that 
CTIP2 hypofunction might contribute to selective MSN pathology in HD. 
See also Figure S4 and Table S4. 
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Supplemental Information Inventory 
Figure S1 (Related to Figures 1 and 3) – Provides information on generation of CTIP2KO hESC lines, 
resulting mutations and confirmation of CTIP2KO as well as confirmation of rescue of CTIP2 
expression in KO lines for Figure 3I Protein analysis. 
Figure S2 (Related to Figure 1) – Provides additional immunostaining data describing subpallial and 
cortical progenitor populations. 
Figure S3 (Related to Figure 2) – Contains RNA-seq data summary (PCA plot and DEG numbers), 
KEGG pathway analysis complementing IPA pathway analysis in the main Figure 2. Also contains 
qPCR validation of differentially expressed genes in the PKA gene set including validation of 2 out of 
4 direct CTIP2 targets in the pathway. 
Figure S4 (Related to Figures 3 and 4) – Presents uncropped western blot images with ladder 
markers that were discussed in the manuscript. 
Table S1 (Related to Figures 2 and S3) – Differentially expressed genes in CTIP2KO MSNs at 20 and 
40 DIV. 
Table S2 (Related to Figures 2, 3 and S3) – Summary of striatal gene set, KEGG gene set and IPA 
canonical pathway enrichment analysis of CTIP2KO DEGs. 
Table S3 (Related to Figures 2, 3 and S3) – Known CTIP2 target genes in CTIP2KO DEGs. 
Table S4 (Related to Figures 4) – Summary of HD dataset enrichment and functional annotation 
analysis of the CTIP2KO-HD DEGs. 
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Supplemental Table Titles and Legends 
Table S1 (Related to Figures 2 and S3) - Differentially expressed genes in CTIP2KO 
MSNs at 20 and 40 DIV. Gene lists are presented in a separate sheet for each time point 
(FDR<0.01). The first three columns identify the gene and the other columns contain 
differential expression statistics for CTIP2KO versus control group comparisons. 
Table S2 (Related to Figures 2, 3 and S3) - Summary of striatal gene set, KEGG gene set 
and IPA canonical pathway enrichment analysis of CTIP2KO DEGs. The first sheet 
provides an overview and Fisher’s exact test statistics for each association with striatal 
dataset tested. Tables #2-7 provide lists of striatum-specific MSN20 and MSN40 DEGs with 
differential expression statistics, each sheet corresponding to one ‘time point’/‘striatal 
dataset’ combination. Tables #8-11 contain one sheet per ‘time point’/analysis combination 
(KEGG or IPA) showing significantly dysregulated pathways (FDR<0.05), enrichment 
statistics and associated gene identifiers.  
Table S3 (Related to Figures 2, 3 and S3) - Known CTIP2 target genes in CTIP2KO 
DEGs. This table contains one sheet per time point showing gene information and differential 
expression statistics. 
Table S4 (Related to Figure 4) - Summary of HD dataset enrichment and functional 
annotation analysis of the CTIP2KO-HD DEGs. The first sheet provides an overview, 
Fisher’s exact test statistics and names of dysregulated genes for each association tested. The 
following two sheets provide a compilation of MSN20 and MSN40 DEGs concordantly 
dysregulated (FDR<0.01) in at least one HD gene expression dataset. Each sheet corresponds 
to one time point and provides gene identifiers with differential expression statistics. Tables 
#4-5 contain one sheet per time point showing significantly dysregulated IPA canonical 
pathways (FDR<0.05), enrichment statistics and associated gene identifiers. 
Supplemental Experimental Procedures  
CRISPR Design and Targeted Mutagenesis 
Guide RNAs (gRNAs) targeting the exon 2 of the CTIP2 gene were selected using Zhang’s lab online CRISPR 
Design tool (http://crispr.mit.edu/; Figure S1A). All gRNAs were synthesized as RNAs by in vitro transcription 
and transfected into iCas9 hESCs as described by Gonzalez et al (Gonzalez et al., 2014). Seven days post-
transfection, individual colonies were isolated and clonally expanded. Genomic DNA was collected for each 
clone and the targeted region was screened by PCR (MyTaq, Bioline; forward primer: 
ACGCTCCGAGCTCAGGAAAG, reverse primer: GCAAGCGCAGCATCCCATAC; amplicon size: 142 bp). 
Genomic DNA samples showing insertions/deletions were then PCR amplified (forward primer: 
GTGGCCAGTGTCAAATGAAC, reverse primer: TCCTCACAGCAACCCTAATG; amplicon size: 706 bp) 
and cloned into a pGEM-T Easy vector (Promega) for Sanger sequencing (GATC Biotech). All studies were 
performed in three homozygous CTIP2-/- lines (#4, #33 and #34, referred to as CTIP2KO) and data is presented 
as the average between the three lines unless stated otherwise. 
CTIP2 rescue 
Transfer plasmid LV#1000-hPGK expressing human CTIP2 was a kind gift from Professor Malin Parmar 
(Lund). Production of lentivirus was performed in HEK293 cells using 2nd generation packaging system and 
following Lipofectamine 3000 kit guidelines (ThermoFisher Scientific). Virus was titrated in HEK cells using 
immunocytochemistry against CTIP2 and the resulting titer was calculated to be 9*109 (U/mL). At 34 DIV, 
control and CTIP2KO MSNs were infected with the virus at a multiplicity of infection of 2 (MOI=number of 
lentiviral particles / number of target cells). At 40 DIV, cells were either fixed for immunocytochemistry or 
processed for protein extraction as described below. 
Cell Culture and MSN Differentiation 
All human pluripotent stem cell (hPSC) lines were maintained in feeder-free conditions on Matrigel-coated 
(Corning) plates in TeSRTM-E8TM medium (STEMCELL Technologies) and passaged via manual dissociation 
using 0.02% EDTA pH7.2 (Merck Sigma-Aldrich). Medium spiny neurons (MSNs) were differentiated from the 
following hPSC lines: HUES9 iCas9 (Gonzalez et al., 2014) and genome edited derivatives (#4, #33, #34), 
SIVF018 [HD hESCs, 46Q (Bradley et al., 2011)], SI-187 [HD hESCs, 51Q (Verlinsky et al., 2005)], ND42228 
[HD hiPSCs, 71Q, RRID:CVCL_1N96 from NHCDR]. MSNs were obtained and maintained as described 
previously (Arber et al., 2015). In short, neural differentiation was initiated by switching TeSRTM-E8TM medium 
to DMEM-F12/Neurobasal (2:1; Thermo Fisher Scientific) supplemented with N2 (Thermo Fisher Scientific) 
and vitamin A-free B27 (Thermo Fisher Scientific) [referred to thereafter as N2B27] and this time point was 
noted as 0 days in vitro (0 DIV). For the first 10 DIV, cultures were supplemented with SB431542 (10 µM, 
Tocris), LDN-193189 (100 nM, StemGent) and dorsomorphin dihydrochloride (200 nM,Tocris). Splitting was 
done en bloc using EDTA at 9 DIV onto fibronectin-coated (Merck Millipore) plates at a ratio of 2:3. MSN fate 
was induced from 10 DIV by supplementing N2B27 medium with activin A (25 ng/ml, Cell Guidance Systems) 
until 30 DIV. Cultures were split again at 20 DIV onto poly-D-lysine hydrobromide (PDL, Merck Sigma-
Aldrich) and laminin (Merck Sigma-Aldrich) co-coated plates at a density of 150k cells/cm2. B27 with vitamin 
A (Thermo Fisher Scientific) was used from 20 DIV onwards. Differentiating MSNs were maintained in N2B27 
supplemented with BDNF, GDNF (10ng/ml, PeproTech) from 25 DIV to aid neuronal maturation and survival. 
Cytotoxicity Assay 
MultiTox-Fluor Multiplex Cytotoxicity Assay (Promega) was performed following manufacturer’s suggestions. 
Briefly, 96-well assay plates containing 40,000 MSN progenitors/well were set up at 20 DIV and cultures 
underwent terminal MSN differentiation. At 40 DIV, test compounds and vehicle controls were added to the 
cells. Treatment groups were as follows: untreated, SNAP (1000 μM) for 24 hours, amentoflavone (50 μM) for 
24 hours, amentoflavone (50 μM) for 2 hours prior to addition of SNAP (1000 μM) for 24 hours (Figure 1G). 
The following controls were also included in each experiment: no cell control to determine background 
fluorescence, vehicle control, positive control for cytotoxicity [cells were treated with digitonin (Merck Sigma-
Aldrich) at a final concentration of 50 µg/ml for 30 minutes]. Cytotoxicity assay reagents were added in an 
equal volume (100 µl/well) to all wells and incubated with samples for 30 minutes at 37°C. Fluorescence 
intensity was then measured on a microplate reader to assess viability (400Ex/505Em) and cell death 
(485Ex/520Em). 
Immunocytochemistry 
Cultured cells were rinsed in PBS and fixed in 3.7% PFA for 15 minutes. Cells were permeabilized in 0.3% 
Triton-X-100 solution in PBS (PBS-T) and then blocked in PBS-T containing 1% BSA and 3% donkey serum. 
Cells were incubated with primary antibodies in blocking solution overnight at 4oC. Following three PBS-T 
washes, Alexa-Fluor secondary antibodies (Thermo Fisher Scientific) were added at 1:1000 in blocking solution 
for 1 hour at ambient temperature in the dark. Cells were stained with DAPI at 1:1000 (Thermo Fisher 
Scientific). The following primary antibodies were used for the immunofluorescence studies: rabbit anti-GSH2 
(Merck Millipore #ABN162, 1:500), goat anti-FOXP2 (Abcam #ab1307, 1:200), mouse anti-ISL1 
(Developmental Studies Hybridoma Bank # 39.4D5, 1:500), goat anti-MEIS2 (Santa Cruz Biotechnology #sc-
10599, 1:250), rabbit anti-FOXP2 (Abcam # ab16046, 1:500), mouse anti-FOXP1 (Abcam # ab32010, 1:800), 
rabbit anti-DARPP32 (Santa Cruz Biotechnology #sc-11365, 1:500), rabbit anti-TBR1 (Abcam # ab31940, 
1:500), mouse anti-ASCL1 (BD Biosciences #556604, 1:500), rat anti-CTIP2 (Abcam # ab18465, 1:500). 
Images were taken on a Zeiss LSM710 confocal microscope from at least 5 randomly selected fields/sample and 
staining quantification was acquired manually in ImageJ (imagej.net) from >5,000 cells/sample blind to the 
experimental condition. 
RNA Sequencing Data Analysis 
Total RNA was extracted from TRIzol lysates using the PureLink RNA mini kit (Ambion) from three biological 
replicates per genotype at 20 and 40 DIV. These time points were chosen to reflect the onset of CTIP2 
expression in nascent post mitotic MSNs and subsequent rapid increase in CTIP2 levels during differentiation, 
as well as to correspond to the time points at which several cellular pathologies have been observed. Paired-end 
sequencing was performed at Oxford Genomic Centre on an Illumina HiSeq 4000 (Illumina, San Diego, USA) 
obtaining a library size of ~80 million reads per sample. FASTQ files were trimmed and mapped to the Ensembl 
human genome GRCh38.84 (hg38) using STAR (v2.5.1b). Quality of the samples was assessed using FastQC 
(v0.11.2) prior to and after trimming. Gene counts were obtained from the number of uniquely aligned 
unambiguous reads by Subread:featureCount (v1.4.6-p2). Library size normalization and differentially 
expressed genes (DEGs) were determined using the R/Bioconductor package DESeq2 (v1.14.1) (Love et al., 
2014). Benjamini-Hochberg (BH) test for multiple correction was used to control the false discovery rate (FDR). 
Subsequent study of KEGG gene set and pathway enrichment analysis was performed on protein coding DEGs 
with an EntrezID and FDR<0.01 using the Ingenuity Pathway Analysis (Qiagen) and R/Bioconductor package 
clusterProfiler (v3.12.14) (Yu et al., 2012). The associations between present CTIP2KO gene sets and published 
striatal and HD gene sets were determined by Fisher’s exact test, performed in RStudio (www.r-project.org). 
PCR Analysis 
Total mRNA was extracted from TRIzol lysates using the PureLink RNA mini kit (Ambion) from three 
biological replicates per line at 40 DIV. RT-PCR was completed using 2 ug mRNA and the EvoScript kit 
(Roche). MesaGreen kit was used to perform qPCR using 200 pg mRNA/reaction to validate CTIP2KO DEGs 
in the PKA gene set. The following primers were used: 
Gene Name Forward Primer Reverse Primer 
MAP2 CAACGGAGAGCTGACCTCA CTACAGCCTCAGCAGTGACTA 
DARPP32 GGTATTTTTATCCGTGCGCGAAC CTTCCTCCTCTGGTGAGGAGTG 
GAD1 CGAGGACTCTGGACAGTAGAGG GATCTTGAGCCCCAGTTTTCTG 
ADD3 CAGCCAAGGCGTGATTACCA TCTTCCCGAAAGGCAGGACT 
CNGA3 GGGACCGGACTCTTTTCCTG CACCACGATCGCATCCTTCT 
DUSP16 ACGATCAAAGCTCCCAAGATGT GCCAGGGAAACAACGAGAGA 
PRKCE CAACGGCCACAAGTTCATGG AGGTGCAGACTTGACACTGG 
ANAPC4 ATTTTCCTGGTCTGGTCGCC CCAGACACGTCACCTCCTTT 
ANAPC5 GGTGCTGCTGAACGAGATGAG GAATTTGCCAGCTGTGGACAAG 
GLI3 GCCTCCAGCACCACTTCTAAT TCAATGAGGCCCTCTCGTCA 
NAPEPLD TCGGAGCTTATGAACCGAGG AGGCAAAAGTTCCCCAGTGA 
PDE3A ACAGGTCTACCCACCTTGGA AGGATCTGCTTTTGGTGAGGG 
PDE5A TGGTGAGCCCTTGAACATCA CTGGGCTACACCAACAACCT 
PRKCQ AAAGGTCCACCACGTCAAGT GTAGCCCTGTTTGTTCAGGC 
PTPRZ1 TTGTTGAAGAGATTGGCTGGTC TTGATAGGAGATTGTTTTGGGCT 
Study Approval 
All animal work was done under UK Home Office personal and project licenses in accordance with the 
requirements of the UK Animals (Scientific Procedures) Act 1986 and European Directive 2010/63/EU and with 
the approval of the local Cardiff University Ethics Review Committee. Animals were group-housed and 
received water and food ad libitum. 
Western Blot Analysis 
At 40 DIV, cells were collected in PBS and lysed on ice in RIPA buffer (Abcam) supplemented with protease 
and phosphatase inhibitors (Merck Sigma-Aldrich). Striatal region was dissected out from adult heterozygous 
HD mice and respective WT littermates (R6/1: 5 months, Q175: 24 months). Tissues were triturated by pipetting 
and lysed as described above. Protein concentrations of whole cell lysates were measured using the DC protein 
assay kit (BioRad) and then combined with 1X Bolt LDS Sample Buffer (Thermo Fisher Scientific) and 1X Bolt 
Sample Reducing Agent (Thermo Fisher Scientific). Equal amounts of proteins for each sample were separated 
on 4-12% Bolt Bis-Tris Plus gels (Thermo Fisher Scientific) and transferred via electro-blotting to a PVDF 
membrane (0.45 µm pore size, GE Healthcare). Membranes were blocked with 5% BSA in TBS containing 
0.1% Tween-20 (TBS-T) for 2 hours at ambient temperature and then incubated with primary antibodies 
overnight at 4°C.  The following primary antibodies were used for the western blot studies: rabbit anti-
pDARPP32-Thr34 (Cell Signaling Technology #12438-D27A4, 1:1000), rabbit anti-DARPP32 (Santa Cruz 
Biotechnology #sc-11365, 1:500), rabbit anti-pGLUR1-Ser845 (Cell Signaling Technology #8084-D10G5, 
1:1000), rabbit anti-GLUR1 (Cell Signaling Technology #13185-D4N9V, 1:1000), mouse anti-PP1α (PPP1CA, 
Santa Cruz Biotechnology #sc-271762, 1:1000), mouse anti-PP2B-Aα (PPP3CA, Santa Cruz Biotechnology 
#sc-17808, 1:1000), mouse anti-PP2B-Aβ (PPP3CB, Santa Cruz Biotechnology #sc-365612, 1:1000), mouse 
anti-PP2B-Aγ (PPP3CC, Santa Cruz Biotechnology #sc-293361, 1:1000), rabbit anti-PKA catalytic subunit 
(PKAcat, Abcam #ab76238, 1:5000), rabbit anti-p35/25 (CDK5R1, Cell Signaling Technology #2680-C64B10, 
1:1000), rabbit anti-MAP2 (Merck Sigma-Aldrich #AB5622, 1:1000), rabbit anti-CTIP2 (Abcam #ab70453, 
1:2000), rat anti-CTIP2 (Abcam # ab18465, 1:1000), mouse anti-GAPDH (Abcam #8245, 1:10000), mouse anti-
β-ACTIN (Merck Sigma-Aldrich #A3854, 1:50000). Following three TBS-T washes, membranes were 
incubated with a horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibody (Abcam) for 1 hour at 
ambient temperature. For CTIP2/GAPDH blotting (Figure S1D), membranes were incubated with anti-rat 
IRDye 800CW and anti-mouse IRDye 680RD secondary antibodies (LI-COR). Blots were developed with ECL 
system (Thermo Fisher Scientific) and imaged on an Odyssey CLx imaging system (LI-COR) or on a Gel Doc 
XR system (Bio-Rad). All images were quantified in ImageJ blind to the experimental condition. 
Statistical Analysis 
RNA sequencing data was analyzed separately as described above. SPSS Statistics 20 software (IBM) was used 
for all other statistical analyses. All quantified data were plotted in Prism 6 (GraphPad Software) and are 
reported as mean ± SEM with sample sizes for each test indicated in the figure legends. Horizontal line on dot 
plots depicts mean ± SEM for each genotype, with the means for individual clones indicated by red-shaded 
circles beside CTIP2KO data. Normal distribution of data was assessed the Shapiro-Wilk test. Statistical 
analysis was performed using one-/two-way ANOVA tests followed by Bonferroni’s correction for multiple 
comparisons if applicable or non-parametric Mann-Whitney test for not normally distributed data. Results were 
considered statistically significant at p<0.05. No statistical methods were used to predetermine sample sizes, but 
our sample sizes are similar to those reported in previous publications (Arber et al., 2015; Cavey et al., 2016; 
Victor et al., 2018). Randomization was used to assign experimental conditions and collect data, and data 
collection was always done in parallel with controls. Data analyses were not performed blind to the conditions 
of the experiments except where stated otherwise. 
Data and Software Availability 
RNA-seq data reported in this paper are available with the SRA accession number SRP150394 
(https://www.ncbi.nlm.nih.gov/sra/SRP150394). No custom algorithms were used to analyze data in this study. 
The authors declare that all data supporting the findings of this study are available within this article, its 
Supplemental Information files, or are available from the corresponding authors upon reasonable request. 
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